IBDEI14Q ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18864,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18864,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,18864,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,18864,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,18865,0)
 ;;=C82.90^^94^916^73
 ;;^UTILITY(U,$J,358.3,18865,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18865,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,18865,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,18865,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,18866,0)
 ;;=R59.1^^94^916^58
 ;;^UTILITY(U,$J,358.3,18866,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18866,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,18866,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,18866,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,18867,0)
 ;;=C91.40^^94^916^77
 ;;^UTILITY(U,$J,358.3,18867,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18867,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,18867,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,18867,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,18868,0)
 ;;=C91.42^^94^916^75
 ;;^UTILITY(U,$J,358.3,18868,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18868,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,18868,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,18868,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,18869,0)
 ;;=C91.41^^94^916^76
 ;;^UTILITY(U,$J,358.3,18869,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18869,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,18869,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,18869,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,18870,0)
 ;;=D57.01^^94^916^78
 ;;^UTILITY(U,$J,358.3,18870,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18870,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,18870,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,18870,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,18871,0)
 ;;=D57.00^^94^916^79
 ;;^UTILITY(U,$J,358.3,18871,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18871,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,18871,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,18871,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,18872,0)
 ;;=D57.02^^94^916^80
 ;;^UTILITY(U,$J,358.3,18872,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18872,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,18872,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,18872,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,18873,0)
 ;;=D68.32^^94^916^82
 ;;^UTILITY(U,$J,358.3,18873,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18873,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,18873,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,18873,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,18874,0)
 ;;=C22.2^^94^916^83
 ;;^UTILITY(U,$J,358.3,18874,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18874,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,18874,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,18874,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,18875,0)
 ;;=D58.9^^94^916^85
 ;;^UTILITY(U,$J,358.3,18875,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18875,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,18875,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,18875,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,18876,0)
 ;;=C81.99^^94^916^86
 ;;^UTILITY(U,$J,358.3,18876,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18876,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,18876,1,4,0)
 ;;=4^C81.99
 ;;^UTILITY(U,$J,358.3,18876,2)
 ;;=^5001460
